Intraperitoneal chemotherapy for stage III ovarian cancer using the gynecologic oncology group protocol 172 intraperitoneal regimen: Effect of supportive care using aprepitant and pegfilgrastim on treatment completion rate

Matthew W. Guile, Amy L. Horne, Sharon D. Thompson, Ginger J. Gardner, Robert L. Giuntoli, Deborah Kay Armstrong, Robert E. Bristow

Research output: Contribution to journalArticle

Abstract

Purpose: We evaluated the outcomes of patients with optimally debulked stage III ovarian cancer receiving intraperitoneal (IP) chemotherapy according to the Gynecologic Oncology Group (GOG) 172 trial with concurrent administration of aprepitant and pegfilgrastim. Patients and Methods: All patients initially treated with GOG 172 IP chemotherapy between March 2005 and August 2006 were retrospectively identified from the tumor registry database. Clinical data pertaining to IP chemotherapy cycle completion, grade 3/4 gastrointestinal (GI) toxicity with relation to aprepitant use, and grade 3/4 neutropenia with relation to pegfilgrastim were abstracted from the medical records. Statistical comparisons were performed using the χ 2 test. Results: Twenty patients were identified. In this group, 102 of 120 (85%) prescribed IP chemotherapy cycles were completed. Sixteen of 20 patients (80%) completed 5-6 cycles of GOG 172 IP therapy. Grade 3/4 neutropenia was documented in 81% of cycles (21 of 26) without pegfilgrastim support. This decreased to 24% of cycles (18 of 76) with pegfilgrastim (P

Original languageEnglish (US)
Pages (from-to)68-71
Number of pages4
JournalClinical Ovarian Cancer
Volume1
Issue number1
DOIs
StatePublished - Jun 2008

Fingerprint

aprepitant
Ovarian Neoplasms
Drug Therapy
Neutropenia
Therapeutics
Medical Records
Registries
pegfilgrastim
Databases

Keywords

  • Antiemetics
  • Epithelial ovarian carcinoma
  • Nausea
  • Neutropenia
  • Vomiting

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Intraperitoneal chemotherapy for stage III ovarian cancer using the gynecologic oncology group protocol 172 intraperitoneal regimen : Effect of supportive care using aprepitant and pegfilgrastim on treatment completion rate. / Guile, Matthew W.; Horne, Amy L.; Thompson, Sharon D.; Gardner, Ginger J.; Giuntoli, Robert L.; Armstrong, Deborah Kay; Bristow, Robert E.

In: Clinical Ovarian Cancer, Vol. 1, No. 1, 06.2008, p. 68-71.

Research output: Contribution to journalArticle

@article{2b9272a63a944b62a2a30d9912bc9f4d,
title = "Intraperitoneal chemotherapy for stage III ovarian cancer using the gynecologic oncology group protocol 172 intraperitoneal regimen: Effect of supportive care using aprepitant and pegfilgrastim on treatment completion rate",
abstract = "Purpose: We evaluated the outcomes of patients with optimally debulked stage III ovarian cancer receiving intraperitoneal (IP) chemotherapy according to the Gynecologic Oncology Group (GOG) 172 trial with concurrent administration of aprepitant and pegfilgrastim. Patients and Methods: All patients initially treated with GOG 172 IP chemotherapy between March 2005 and August 2006 were retrospectively identified from the tumor registry database. Clinical data pertaining to IP chemotherapy cycle completion, grade 3/4 gastrointestinal (GI) toxicity with relation to aprepitant use, and grade 3/4 neutropenia with relation to pegfilgrastim were abstracted from the medical records. Statistical comparisons were performed using the χ 2 test. Results: Twenty patients were identified. In this group, 102 of 120 (85{\%}) prescribed IP chemotherapy cycles were completed. Sixteen of 20 patients (80{\%}) completed 5-6 cycles of GOG 172 IP therapy. Grade 3/4 neutropenia was documented in 81{\%} of cycles (21 of 26) without pegfilgrastim support. This decreased to 24{\%} of cycles (18 of 76) with pegfilgrastim (P",
keywords = "Antiemetics, Epithelial ovarian carcinoma, Nausea, Neutropenia, Vomiting",
author = "Guile, {Matthew W.} and Horne, {Amy L.} and Thompson, {Sharon D.} and Gardner, {Ginger J.} and Giuntoli, {Robert L.} and Armstrong, {Deborah Kay} and Bristow, {Robert E.}",
year = "2008",
month = "6",
doi = "10.3816/COC.2008.n.00",
language = "English (US)",
volume = "1",
pages = "68--71",
journal = "Clinical Ovarian Cancer",
issn = "2212-9553",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Intraperitoneal chemotherapy for stage III ovarian cancer using the gynecologic oncology group protocol 172 intraperitoneal regimen

T2 - Effect of supportive care using aprepitant and pegfilgrastim on treatment completion rate

AU - Guile, Matthew W.

AU - Horne, Amy L.

AU - Thompson, Sharon D.

AU - Gardner, Ginger J.

AU - Giuntoli, Robert L.

AU - Armstrong, Deborah Kay

AU - Bristow, Robert E.

PY - 2008/6

Y1 - 2008/6

N2 - Purpose: We evaluated the outcomes of patients with optimally debulked stage III ovarian cancer receiving intraperitoneal (IP) chemotherapy according to the Gynecologic Oncology Group (GOG) 172 trial with concurrent administration of aprepitant and pegfilgrastim. Patients and Methods: All patients initially treated with GOG 172 IP chemotherapy between March 2005 and August 2006 were retrospectively identified from the tumor registry database. Clinical data pertaining to IP chemotherapy cycle completion, grade 3/4 gastrointestinal (GI) toxicity with relation to aprepitant use, and grade 3/4 neutropenia with relation to pegfilgrastim were abstracted from the medical records. Statistical comparisons were performed using the χ 2 test. Results: Twenty patients were identified. In this group, 102 of 120 (85%) prescribed IP chemotherapy cycles were completed. Sixteen of 20 patients (80%) completed 5-6 cycles of GOG 172 IP therapy. Grade 3/4 neutropenia was documented in 81% of cycles (21 of 26) without pegfilgrastim support. This decreased to 24% of cycles (18 of 76) with pegfilgrastim (P

AB - Purpose: We evaluated the outcomes of patients with optimally debulked stage III ovarian cancer receiving intraperitoneal (IP) chemotherapy according to the Gynecologic Oncology Group (GOG) 172 trial with concurrent administration of aprepitant and pegfilgrastim. Patients and Methods: All patients initially treated with GOG 172 IP chemotherapy between March 2005 and August 2006 were retrospectively identified from the tumor registry database. Clinical data pertaining to IP chemotherapy cycle completion, grade 3/4 gastrointestinal (GI) toxicity with relation to aprepitant use, and grade 3/4 neutropenia with relation to pegfilgrastim were abstracted from the medical records. Statistical comparisons were performed using the χ 2 test. Results: Twenty patients were identified. In this group, 102 of 120 (85%) prescribed IP chemotherapy cycles were completed. Sixteen of 20 patients (80%) completed 5-6 cycles of GOG 172 IP therapy. Grade 3/4 neutropenia was documented in 81% of cycles (21 of 26) without pegfilgrastim support. This decreased to 24% of cycles (18 of 76) with pegfilgrastim (P

KW - Antiemetics

KW - Epithelial ovarian carcinoma

KW - Nausea

KW - Neutropenia

KW - Vomiting

UR - http://www.scopus.com/inward/record.url?scp=84860593494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860593494&partnerID=8YFLogxK

U2 - 10.3816/COC.2008.n.00

DO - 10.3816/COC.2008.n.00

M3 - Article

AN - SCOPUS:84860593494

VL - 1

SP - 68

EP - 71

JO - Clinical Ovarian Cancer

JF - Clinical Ovarian Cancer

SN - 2212-9553

IS - 1

ER -